The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Positive cerebrospinal fluid (CSF) biomarkers of tau and amyloid beta42 suggest possible active underlying Alzheimer’s Disease (AD) including neurometabolic dysfunction and neurodegeneration leading to eventual cognitive decline. But the temporal relationship between CSF, imaging markers of neural function, and cognition has not been described. Using a statistical mediation model, we examined relationships between cerebrospinal fluid (CSF) analytes (hyperphosphorylated tau (p-Tau181p), β-amyloid 1–42 (Aβ1–42), total tau (t-Tau), and their ratios); change in cognitive function; and change in [18F]fluorodeoxyglucose (FDG) uptake using positron emission tomography (PET). We hypothesized that a) abnormal CSF protein values at baseline, result in cognitive declines by decreasing neuronal glucose metabolism across time, and b) the role of altered glucose metabolism in the assumed causal chain varies by brain region and the nature of CSF protein alteration. Data from 412 individuals participating in Alzheimer’s Disease Neuroimaging (ADNI) cohort studies were included in analyses. At baseline, individuals were cognitively normal (N = 82), or impaired: 241 with mild cognitive impairment, and 89 with Alzheimer’s disease. A parallel-process latent growth curve model was used to test mediational effects of changes in regional FDG-PET uptake over time in relation to baseline CSF biomarkers and changes in cognition, measured with the 13-item Alzheimer Disease’s Assessment Scale–cognitive subscale (ADAS-Cog). Findings suggested a causal sequence of events; specifically, FDG hypometabolism acted as a mediator between antecedent CSF biomarker alterations and subsequent cognitive impairment. Higher baseline concentrations of t-Tau, and p-Tau181p were more predictive of decline in cerebral glucose metabolism than lower baseline concentrations of Aβ1–42. FDG-PET changes appeared to mediate t-Tau or t-Tau/Aβ1–42 -associated cognitive change across all brain regions examined. Significant direct effects of alterations in Aβ1–42 levels on hypometabolism were observed in a single brain region: middle/inferior temporal gyrus. Results support a temporal framework model in which reduced CSF amyloid-related biomarkers occur earlier in the pathogenic pathway, ultimately leading to detrimental cognitive effects. Also consistent with this temporal framework model, baseline markers of neurofibrillary degeneration predicted changes in brain glucose metabolism in turn causing longitudinal cognitive changes, suggesting that tau-related burden precedes neurometabolic dysfunction. While intriguing, the hypothesized mediational relationships require further validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
A general approach to causal mediation analysis.
Imai, K., Keele, L., & Tingley, D. (2010) · Psychological Methods · doi:10.1037/a0020761 · Cited by 4,143
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“…adults (Craig-Schapiro et al., 2010; Fagan et al., 2007; Li et al., 2007; Roe et al., 2013), conversion from mild cognitive impairment (MCI) to AD (Hansson et al., 2006), and faster progression of functional and cognitive deficits in individuals with incipient dementia of the Alzheimer type…”
A practical and theoretical guide to measurement invariance in aging research
Horn, J. L., & Mcardle, J. J. (1992) · Experimental Aging Research · doi:10.1080/03610739208253916 · Cited by 1,592 · cited 1×
“To insure unambiguous interpretation of changes in the ADAS–Cog-13 between time points, we conducted longitudinal measurement invariance tests over a 36-month interval to determine whether the test items assessed the same attribute across time (Horn and McArdle, 1992; Meredith, 1993).”
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 2×
“Previous research (Reiman et al., 2001, 1996; Small et al., 2000) has demonstrated a link between ApoE ε4 carriers and lower cerebral glucose metabolism as compared to ApoE ε4 non-carriers.”
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“…p-Tau181p/Aβ1–42 and/or t-Tau/Aβ1–42 predict cognitive impairment within a few years of onset in non-demented older adults (Craig-Schapiro et al., 2010; Fagan et al., 2007; Li et al., 2007; Roe et al., 2013), conversion from mild cognitive impairment (MCI) to AD (Hansson et al., 2006), and faster…”
Mediation Models for Longitudinal Data in Developmental Research
Selig, J. P., & Preacher, K. J. (2009) · Research in Human Development · doi:10.1080/15427600902911247 · Cited by 804
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 1×
“Previous research (Reiman et al., 2001, 1996; Small et al., 2000) has demonstrated a link between ApoE ε4 carriers and lower cerebral glucose metabolism as compared to ApoE ε4 non-carriers.”
Cited by
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Self-citationBrain fluorodeoxyglucose (FDG) PET in dementia
Kato, T., Inui, Y., Nakamura, A., & Ito, K. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.003 · Cited by 236
Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133
“Published by Elsevier Inc. on behalf of the Alzh ns.org/licenses/by/4.0/). glucose metabolism assessed using fluorodeoxyglucose (FDG) PET [4], and increases in CSF proteins that may reflect damage, for example, Tau and neurofilament light (Nfl) [5,6].”
BackgroundInfluential
Metadata
- Authors
- Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. J.
- Venue
- NeuroImage
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 105
- Pages
- 357-368
- ISSN
- 1053-8119 (ISSN-L)
- OpenAlex
- W2055197036
- Cited by
- 43
- References
- 30
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. https://app.cochat.ai/papers/10.1016/j.neuroimage.2014.10.050
- The paper
- Dowling, N. M., Johnson, S. C., Gleason, C. E., & Jagust, W. J. (2015). The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function. NeuroImage. https://doi.org/10.1016/j.neuroimage.2014.10.050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.